XNAS
ALEC
Market cap224mUSD
Oct 08, Last price
2.02USD
1D
5.21%
1Q
25.47%
IPO
-87.61%
Name
Alector Inc
Chart & performance
P/E
—
P/S
10.66
EPS
—
Div yield, %
—
Shrs. gr., 5y
5.78%
Rev. gr., 5y
-0.05%
Revenues
21m
-79.07%
Net income
-143m
L+20.06%
CFO
-184m
L-19.95%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Key people
Chairman of the Board, Co-Founder · since 2013
President, Chief Operating Officer · since 2019
Calvin Yu
Vice President - Finance · since 2017
Sabah Oney
Chief Business Officer · since 2016
Robert Paul
Chief Medical Officer · since 2016
Arnon Rosenthal
President, Chief Executive Officer, Co-Founder, Director · since 2013
David M. Wehner
Independent Director · since 2018
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
CORPORATION TRUST CENTER 1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
151 Oyster Point Boulevard
Suite 300
South San Francisco, CA 94080
US
Suite 300
South San Francisco, CA 94080
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||